The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Thomas Kukar
Project Title: Mechanisms of Progranulin loss in FTD and AD
Date: [208]
Request ID: T1711
Aim 1: Determine levels of progranulin and granulins in fibroblasts and iPSCs from sporadic and genetically defined FTD (GRN mutations) and AD
Aim 2: Determine levels of progranulin and granulins in post-mortem brain tissue defined FTD (GRN mutations; FUS mutations) and AD
Aim 3:
Aim 4:
Investigator: Randall Bateman
Project Title: In Vivo Metabolism of Abeta
Date: [208]
Request ID: T1710
Aim 1: 1) Aim 1: To replicate findings in a separate cohort that plasma A� concentrations (specifically A�42 and A�42/40 ratio) as measured by the Bateman lab N15 mass spectrometry protocol to determine sensitivity and specificity to identify amyloidosis.
Aim 2: 2) Aim 2: To replicate findings in a younger cohort with moderate risk (25%-35% risk of amyloid deposition as measured by amyloid PET) of amyloidosis as measured by the Bateman lab N15 mass spectrometry protocol to determine sensitivity and specificity to identify amyloidosis.
Aim 3: 3) If aims 1 and 2 are successful, then plans to determine longitudinal change of the plasma A� biomarker will be undertaken to assess stability and rate of change of the plasma A� biomarker.
Aim 4: 4) Aim 4: If all the above aims are successful, in order to further validate a potential plasma biomarker, we request EDTA plasma and CSF samples that were collected at the same time, which are not included in aims 1-3.
Investigator: John Crary
Project Title: Regulation of Tau Expression in PSP
Date: [208]
Request ID: T1709 Crary
Aim 1: To identify risk alleles for PSP
Aim 2: To characterize the functional implications of genetic changes on gene expression and protein expression in PSP
Aim 3:
Aim 4:
Investigator: Norelle C. Wildburger
Project Title: In vivo metabolic imaging of Aβ deposition and toxicity
Date: [208]
Request ID: T1708 Bateman
Aim 1: Quantify in vivo Aβ proteoform deposition from human Alzheimer�s disease using stable isotope label kinetics
Aim 2: Build a computational mathematical framework that accurately quantifies 13C6-leucine-labeled Abeta deposition into the insoluble abeta fraction in human AD brain
Aim 3:
Aim 4:
Investigator: Eva Hajos-Korcsok
Project Title: Cerebrospinal fluid request (CSF amyloid-beta panel)
Date: [208]
Request ID: T1607-A
Aim 1: Additional biomarker analysis of residual CSF samples from ADRC#T1607
Aim 2: Cross-sectional analysiss of CSF Ab42:37 ratio across AD continuum
Aim 3: Longitudinal analysis of CSF Ab42:37 ratio in subjects that convert to AD
Aim 4:
Investigator: Timothy M. Miller
Project Title: Generation of a PET Tracer for TDP-43 Aggregates for ALS and FTD
Date: [208]
Request ID: T1707
Aim 1: Develop bioassays to assess binding affinity to aggregated TDP-43
Aim 2: Identify lead compounds with high binding affinity to aggregated TDP-43
Aim 3: Synthesis of TDP-43 targeted PET radiopharmaceuticals and assessment of radiochemistry, BBB permeability, and binding affinity to aggregated TDP-43
Aim 4: Optimization of lead TDP-43 PET radiopharmaceuticals via pharmacokinetic studies in rodent models
Investigator: Zhude Tu
Project Title: Upregulation of neuroinflammation linking Alzheimer disease and comorbid depression
Date: [208]
Request ID: T1706
Aim 1: In vitro measure 3H-PBR28 brain binding in the presence of depression in AD cases
Aim 2:
Aim 3:
Aim 4:
Investigator: Jinbin Xu
Project Title: Postmortem Validation of Biomarkers for Imaging AD and PD
Date: [208]
Request ID: T1705
Aim 1: Conduct quantitative autoradiography and mRNA measures to compare the protein levels and gene expression of VMAT2, DAT, dopamine D1, D2, D3 (high- and low-af?nity state receptors), D4 receptors and VAChT densities in frozen sections from postmortem human AD, PD and healthy control cases.
Aim 2:
Aim 3:
Aim 4:
Investigator: Byron Caughey
Project Title: Development of tau RT-QuIC assays for tau oligomers with seeding activity
Date: [208]
Request ID: T1703 Caughey
Aim 1: To develop seeded polymerization-based assay for tauopathy-associated tau aggregates.
Aim 2: To improve the sensitivity and specificity of tauopathy diagnostics.
Aim 3: To improve the detection of tau aggregates as biomarkers to facilitate therapeutic trials.
Aim 4:
Investigator: Kaj Blennow
Project Title: Plasma NFL as a biomarker for preclinical AD
Date: [208]
Request ID: T1704
Aim 1: Study plasma NFL as a predictor of progression in the preclinical stage
Aim 2: Study plasma NFL as a neurodegeneration biomarker in MCI
Aim 3:
Aim 4: